BackBlackRock Health Sciences Trust Overview
BlackRock Health Sciences Trust

BlackRock Health Sciences Trust Price to Sales

Valuation check: BME's P/S ratio is 11.53, above the sector sector average of 10.99.

Get informed when a big investor buys or sells

+ Follow

Price to Sales

11.53

Price to Sales

11.53

Price-to-Sales ratio compares a company's stock price to its revenue per share. A lower P/S ratio may indicate that the stock is undervalued relative to its sales.

Price to Sales (Comparison Companies)

Loading

Price to Sales History

Loading

Price to Sales Comparison

Loading

BlackRock Health Sciences Trust (BME) FAQ

BlackRock Health Sciences Trust's price-to-sales ratio stands at 11.53. That is above the sector sector average of 10.99. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

BlackRock Health Sciences Trust sits higher the its sector benchmark (10.99) with a P/S ratio of 11.53. That is roughly 5.0% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether 11.53 is attractive depends on BlackRock Health Sciences Trust's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how BlackRock Health Sciences Trust's P/S ratio evolved across reporting periods, while the comparison chart places BME next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.